Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1568449

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1568449

3D Bioprinting Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 5350
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

The Global 3D Bioprinting Market size is expected to record a 16.7% CAGR between 2024 and 2032, driven by technological advancements and a surge in product launches.

3D bioprinting is undergoing rapid expansion, with the introduction of novel bioprinting technologies facilitating intricate tissue engineering. These advancements bolster the accuracy of biological structure replication, broadening the scope of 3D bioprinting applications in medical research and therapies. For example, in November 2023, Avay Biosciences unveiled a groundbreaking 3D printer, engineered to print human tissues. This innovation propels the fields of tissue engineering and regenerative medicine, offering unparalleled precision and functionality in bioprinting.

The 3D bioprinting industry is segmented based on component, application, technology, material, end-use, and region.

The market share from the inkjet bioprinting technology segment is expected to witness substantial growth through 2032, driven by its rising adoption to bolster 3D bioprinting capabilities. The inkjet bioprinting method employs inkjet printers to layer bio inks, crafting intricate tissue structures with precision. As the technology evolves, it will also branch into areas like personalized medicine and regenerative therapies. This innovation paves the way for crafting fully functional tissues and organs, revolutionizing medical research and treatment methodologies.

In terms of end-use, the 3D bioprinting market value from the hospitals segment is slated to generate notable revenue during 2024-2032, favored by their increasing preference to elevate patient care and medical procedures. Hospitals are leveraging 3D bioprinting to produce tailored implants, prosthetics, and intricate tissue structures, enhancing treatment precision and effectiveness. By offering patient-specific solutions aligned with individual anatomical needs, 3D bioprinting is boosting the success rates of surgeries and treatments.

Europe 3D bioprinting industry size is likely to record a notable CAGR through 2032 driven by increasing regulatory support. Regulatory bodies are working to establish guidelines and frameworks to facilitate the development and application of 3D bioprinting in medical and research fields. The continuous improvement of regulatory frameworks is also supporting ongoing advancements for driving the growth and application of 3D bioprinting technology across various sectors in Europe.

Product Code: 10305

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360°synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing demand for organ transplants and tissue regeneration
      • 3.2.1.2 Advancements in bioprinting technologies
      • 3.2.1.3 Increased biotechnology and pharmaceutical R and D investments
      • 3.2.1.4 Growing demand for personalized medicines
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High costs associated with 3D bioprinting equipment and materials
      • 3.2.2.2 Regulatory and ethical challenges associated with bioprinted tissues and organs
  • 3.3 Growth potential analysis
  • 3.4 Reimbursement scenario
  • 3.5 Future market trends
  • 3.6 Regulatory landscape
  • 3.7 Technological landscape
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Component, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 3D bioprinters
  • 5.3 Bioinks
  • 5.4 Software
  • 5.5 Consumables

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Clinical applications
    • 6.2.1 Regenerative medicine
    • 6.2.2 Orthopedic implants
    • 6.2.3 Dental implants
    • 6.2.4 Cosmetic surgery
  • 6.3 Non-clinical applications
    • 6.3.1 Drug discovery
    • 6.3.2 Drug research

Chapter 7 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Inkjet bioprinting
  • 7.3 Microextrusion bioprinting
  • 7.4 Laser-assisted bioprinting
  • 7.5 Magnetic levitation bioprinting
  • 7.6 Stereolithography

Chapter 8 Market Estimates and Forecast, By Material, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hydrogels
  • 8.3 Living cells
  • 8.4 Extracellular matrices
  • 8.5 Bioplastics

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospitals
  • 9.3 Academic and research institutes
  • 9.4 Pharmaceutical and biotechnology companies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
    • 10.5.4 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Advanced Solutions Life Sciences, LLC
  • 11.2 Allevi, Inc.
  • 11.3 Aspect Biosystems Ltd.
  • 11.4 BICO Group AB
  • 11.5 Brinter
  • 11.6 CollPlant Biotechnologies Ltd.
  • 11.7 CYFUSE BIOMEDICAL K.K.
  • 11.8 ENVISIONTEC US LLC
  • 11.9 Inventia Life Science Pty Ltd.
  • 11.10 Merck KGaA
  • 11.11 Organovo Holdings, Inc.
  • 11.12 Poietis
  • 11.13 regenHU
  • 11.14 Rokit Healthcare, Inc.
  • 11.15 3D Systems Corporation
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!